STD Information Center > STD News > Prevention of HPV

Prevention of Genital Human Papillomavirus Infection
Report to Congress Page 5

Reference List

(1) Cates W, Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sexually Transmitted Diseases 1999; 26(4:Suppl):Suppl-7.

(2) NIH Consensus Statement Online 1996 April 1-3 [October 28, 2003]. pp 1-38.

(3) World Health Organization. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses. [64]. 1995. Lyons, IARC.

(4) Daling JR, Weiss NS, Klopfenstein LL, Cochran LE, Chow WH, Daifuku R. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982; 247(14):1988-1990.

(5) Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. New England Journal of Medicine 1987; 317(16):973-977.

(6) Holly EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ, Kristiansen JJ. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. Journal of the National Cancer Institute 1989; 81(22):1726-1731.

(7) Koblin BA, Hessol NA, Zauber AG, Taylor PE, Buchbinder SP, Katz MH et al. Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990. American Journal of Epidemiology 1996; 144(10):916-923.

(8) Ries L, Kosery C, Hankey B, MillerB, Clegg L, Edwards B. SEER Cancer Statistics Review 1973-1996. Bethesda, MD: National Cancer Institute, 1999.

(9) Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. Journal of the National Cancer Institute 2003; 95(23):1772-1783.

(10) Syrjanen KJ. HPV infections and oesophageal cancer. Journal of Clinical Pathology 2002; 55(10):721-728.

(11) Cuzick J. Human papillomavirus infection of the prostate. Cancer Surveys 1995; 23:91-95.

(12) Adami HO, Kuper H, Andersson SO, Bergstrom R, Dillner J. Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiology, Biomarkers & Prevention 2003; 12(9):872-875.

(13) Rosenblatt KA, Carter JJ, Iwasaki LM, Galloway DA, Stanford JL. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 2003; 12(8):763-768.

(14) Division of STD Prevention. Prevention of Genital HPV Infection and Sequelae: Report of an External Consultants' Meeting. 1999. Atlanta, GA., Department of Health and Human Services, Atlanta: Centers for Disease Control and Prevention (CDC).

(15) Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiologic Reviews 1988; 10:122-163.

(16) Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. American Journal of Epidemiology 2000; 151(12):1158-1171.

(17) Weinstock H, Berman S, cates W. Sexually Transmitted Infections in American Youth: Incidence and Prevalence Estimates, 2000. Perspectives on Sexual and Reproductive Health. In press.

(18) Fairley CK, Chen S, Tabrizi SN, Leeton K, Quinn MA, Garland SM. The absence of genital human papillomavirus DNA in virginal women. International Journal of STD & AIDS 1992; 3(6):414-417.

(19) Rylander E, Ruusuvaara L, Almstromer MW, Evander M, Wadell G. The absence of vaginal human papillomavirus 16 DNA in women who have not experienced sexual intercourse. Obstetrics & Gynecology 1994; 83(5:Pt 1):1-7.

(20) Koutsky LA, Kiviat NB. Genital human papillomavirus. In: Holmes KK, Sparling PF, Mardh PA et al, editors. Sexually Transmitted Diseases. New York: McGraw-Hill, 1999: 347-359.

(21) Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. American Journal of Epidemiology 2003; 157(3):218-226.

(22) Baken LA, Koutsky LA, Kuypers J, Kosorok MR, Lee SK, Kiviat NB et al. Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. Journal of Infectious Diseases 1995; 171(2):429-432.

(23) Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991; 265(4):472-477.

(24) Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sexually Transmitted Diseases 1993; 20(5):274-278.

(25) Ley C, Bauer HM, Reingold A, Schiffman MH, Chambers JC, Tashiro CJ et al. Determinants of genital human papillomavirus infection in young women. Journal of the National Cancer Institute 1991; 83(14):997-1003.

(26) Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ et al. Determinants of genital human papillomavirus detection in a US population. Journal of Infectious Diseases 2001; 183(11):1554-1564.

(27) Wheeler CM, Parmenter CA, Hunt WC, Becker TM, Greer CE, Hildesheim A et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sexually Transmitted Diseases 1993; 20(5):286-289.

(28) Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. New England Journal of Medicine 1998; 338(7):423-428.

(29) Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. Journal of Infectious Diseases 2002; 186(4):462-469.

(30) Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz JA et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sexually Transmitted Diseases 1996; 23(4):333-341.

(31) Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285(23):2995-3002.

(32) Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. Journal of Infectious Diseases 2001; 184(12):1508-1517.

(33) Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. Journal of Infectious Diseases 1999; 180(5):1415-1423.

(34) Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. Journal of the National Cancer Institute 2000; 92(6):464-474.

(35) Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S et al. Incidence, clearance and predictors of human papillomavirus infection in women.[comment]. CMAJ Canadian Medical Association Journal 2003; 168(4):421-425.

(36) Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357(9271):1831-1836.

(37) Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ Canadian Medical Association Journal 2001; 164(7):1017-1025.

(38) Fairley CK, Chen S, Ugoni A, Tabrizi SN, Forbes A, Garland SM. Human papillomavirus infection and its relationship to recent and distant sexual partners. Obstetrics & Gynecology 1994; 84(5):755-759.

(39) Davidson M, Schnitzer PG, Bulkow LR, Parkinson AJ, Schloss ML, Fitzgerald MA et al. The prevalence of cervical infection with human papillomaviruses and cervical dysplasia in Alaska Native women. Journal of Infectious Diseases 1994; 169(4):792-800.

(40) Fairley CK, Chen S, Tabrizi SN, McNeil J, Becker G, Walker R et al. Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment. Nephrology Dialysis Transplantation 1994; 9(4):416-420.

(41) Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T, Crowley-Nowick PA et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Archives of Pediatrics & Adolescent Medicine 2000; 154(2):127-134.

(42) Jamieson DJ, Duerr A, Burk R, Klein RS, Paramsothy P, Schuman P et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. American Journal of Obstetrics & Gynecology 2002; 186(1):21-27.

(43) Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC, Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. New England Journal of Medicine 1997; 337(19):1343-1349.

(44) Aynaud O, Poveda JD, Huynh B, Guillemotonia A, Barrasso R. Frequency of herpes simplex virus, cytomegalovirus and human papillomavirus DNA in semen. International Journal of STD & AIDS 2002; 13(8):547-550.

(45) Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Kornegay JR et al. Human papillomavirus infection in men attending a sexually transmitted disease clinic. Journal of Infectious Diseases 2003; 187(7):1064-1070.

(46) Castellsague X, Bosch FX, Munoz N, Meijer CJ, Shah KV, de Sanjose S et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. New England Journal of Medicine 2002; 346(15):1105-1112.

(47) Fife KH, Coplan PM, Jansen KU, DiCello AC, Brown DR, Rojas C et al. Poor sensitivity of polymerase chain reaction assays of genital skin swabs and urine to detect HPV 6 and 11 DNA in men. Sexually Transmitted Diseases 2003; 30(3):246-248.

(48) Hippelainen M, Syrjanen S, Hippelainen M, Koskela H, Pulkkinen J, Saarikoski S et al. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sexually Transmitted Diseases 1993; 20(6):321-328.

(49) Lazcano-Ponce E, Herrero R, Munoz N, Hernandez-Avila M, Salmeron J, Leyva A et al. High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples. Sexually Transmitted Diseases 2001; 28(5):277-280.

(50) Olatunbosun O, Deneer H, Pierson R. Human papillomavirus DNA detection in sperm using polymerase chain reaction. Obstetrics & Gynecology 2001; 97(3):357-360.

(51) Rintala MA, Pollanen PP, Nikkanen VP, Grenman SE, Syrjanen SM. Human papillomavirus DNA is found in the vas deferens. Journal of Infectious Diseases 2002; 185(11):1664-1667.

(52) Svare EI, Kjaer SK, Worm AM, Osterlind A, Meijer CJ, van den Brule AJ. Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sexually Transmitted Infections 2002; 78(3):215-218.

(53) Wikstrom A, Popescu C, Forslund O. Asymptomatic penile HPV infection: a prospective study. International Journal of STD & AIDS 2000; 11(2):80-84.

(54) Van Doornum GJ, Prins M, Juffermans LH, Hooykaas C, van den Hoek JA, Coutinho RA et al. Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourinary Medicine 1994; 70(4):240-246.

(55) Weaver BA, Feng Q, Holmes KK, Kiviat N, Lee S, Meyer C et al. Evaluation of Genital Sites and Sampling Techniques for HPV DNA Detection in Men. Journal of Infectious Diseases. In press.

(56) Perez J, Trigg B, Wheeler C. Detection of Genital Human Papillomavirus (HPV) in Men Using Different Sampling Strategies. [Abstract P 090] International Papillomavirus Conference, October 4-9, 2002, Paris, France.

(57) Weaver B, Feng Q, Kiviat N, Holmes K, Lee S, Meyer C et al. Evaluation of genital sampling techniques for HPV DNA detection. [Abstract O019] International Papillomavirus Conference October 4-9, 2002. Paris, France.

(58) Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. Journal of Infectious Diseases 2000; 181(6):1911-1919.

(59) Wideroff L, Schiffman M, Haderer P, Armstrong A, Greer CE, Manos MM et al. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. Journal of Infectious Diseases 1999; 180(5):1424-1428.

(60) Wideroff L, Schiffman MH, Hoover R, Tarone RE, Nonnenmacher B, Hubbert N et al. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. Journal of Infectious Diseases 1996; 174(5):937-943.

(61) Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER et al. Seroprevalence of Human Papillomavirus Type 16 Infection in the United States. Journal of Infectious Diseases 2002; 186.

(62) Slavinsky J, III, Kissinger P, Burger L, Boley A, DiCarlo RP, Hagensee ME. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. International Journal of STD & AIDS 2001; 12(8):516-523.

(63) Chuang TY, Perry HO, Kurland LT, Ilstrup DM. Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features. Archives of Dermatology 1984; 120(4):469-475.

(64) Koutsky L. Epidemiology of genital human papillomavirus infection. American Journal of Medicine 1997; 102(5A):3-8.

(65) Armstrong LR, Preston EJ, Reichert M, Phillips DL, Nisenbaum R, Todd NW et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clinical Infectious Diseases 2000; 31(1):107-109.

(66) ACS. Cancer Facts and Figures 2003.

(67) Molano M, Van den BA, Plummer M, Weiderpass E, Posso H, Arslan A et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. American Journal of Epidemiology 2003; 158(5):486-494.

(68) Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. Journal of Pediatrics 1998; 132(2):277-284.

(69) Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. Journal of the National Cancer Institute 1995; 87(18):1365-1371.

(70) Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. Journal of Infectious Diseases 1994; 169(2):235-240.

(71) Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. Journal of the National Cancer Institute 2003; 95(17):1336-1343.

(72) Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. New England Journal of Medicine 1992; 327(18):1272-1278.

(73) Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. International Journal of Gynecological Pathology 1993; 12(2):186-192.

(74) Munoz N. Human papillomavirus and cancer: the epidemiological evidence. Journal of Clinical Virology 2000; 19(1-2):1-5.

(75) Munoz N, Bosch FX. Epidemiology of cervical cancer. IARC Scientific Publications 1989;(94):9-39.

(76) Smith JS, Green J, Berrington dG, Appleby P, Peto J, Plummer M et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361(9364):1159-1167.

(77) Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV carcinogenesis. Virus Research 2002; 89(2):191-199.

(78) Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. Journal of the National Cancer Institute Monographs 2003;(31):20-28.

(79) Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. British Journal of Cancer 2001; 84(9):1219-1226.

(80) Sedjo RL, Fowler BM, Schneider A, Henning SM, Hatch K, Giuliano AR. Folate, vitamin B12, and homocysteine status. findings of no relation between human papillomavirus persistence and cervical dysplasia. Nutrition 2003; 19(6):497-502.

(81) Castle PE, Giuliano AR. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients--assessing their roles as human papillomavirus cofactors. [Review] [50 refs]. Journal of the National Cancer Institute Monographs 2003;(31):29-34.

(82) Smith JS, Munoz N, Herrero R, Eluf-Neto J, Ngelangel C, Franceschi S et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. Journal of Infectious Diseases 2002; 185(3):324-331.

(83) Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. Journal of the National Cancer Institute Monographs 2003;(31):14-19.

(84) Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Boden E et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sexually Transmitted Diseases 1995; 22(2):119-127.

(85) Castle PE, Shields T, Kirnbauer R, Manos MM, Burk RD, Glass AG et al. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sexually Transmitted Diseases 2002; 29(3):182-187.

(86) Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. Journal of Infectious Diseases 1996; 174(4):679-689.

(87) Jamison JH, Kaplan DW, Hamman R, Eagar R, Beach R, Douglas JM, Jr. Spectrum of genital human papillomavirus infection in a female adolescent population. Sexually Transmitted Diseases 1995; 22(4):236-243.

(88) Coutlee F, Trottier AM, Ghattas G, Leduc R, Toma E, Sanche G et al. Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sexually Transmitted Diseases 1997; 24(1):23-31.

(89) Fairley CK, Gay NJ, Forbes A, Abramson M, Garland SM. Hand-genital transmission of genital warts? An analysis of prevalence data. Epidemiology & Infection 1995; 115(1):169-176.

(90) Marrazzo JM, Stine K, Koutsky LA. Genital human papillomavirus infection in women who have sex with women: a review. American Journal of Obstetrics & Gynecology 2000; 183(3):770-774.

(91) Watts DH, Koutsky LA, Holmes KK, Goldman D, Kuypers J, Kiviat NB et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. American Journal of Obstetrics & Gynecology 1998; 178(2):365-373.

(92) af G, V, Eklund C, Wang Z, Sapp M, Schiller JT, Dillner J et al. A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. International Journal of Cancer 1999; 80(4):489-493.

(93) Ferenczy A, Bergeron C, Richart RM. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. Obstetrics & Gynecology 1989; 74(6):950-954.

(94) Roden RB, Lowy DR, Schiller JT. Papillomavirus is resistant to desiccation. Journal of Infectious Diseases 1997; 176(4):1076-1079.

(95) Bergeron C, Ferenczy A, Richart R. Underwear: contamination by human papillomaviruses. American Journal of Obstetrics & Gynecology 1990; 162(1):25-29.

(96) Ferenczy A, Bergeron C, Richart RM. Carbon dioxide laser energy disperses human papillomavirus deoxyribonucleic acid onto treatment fields. American Journal of Obstetrics & Gynecology 1990; 163(4:Pt 1):t-4.

(97) Eddy DM. Screening for cervical cancer. Annals of Internal Medicine 1990; 113(3):214-226.

(98) Kiviat N, Koutsky L, Paavonen J. Cervical Neoplasia and Other STD-Related Genital Tract Neoplasias. Sexually Transmitted Diseases. 3rd Edition. New York: McGraw-Hill, 1999: 811-832.

(99) Garnett GP, Anderson RM. Sexually transmitted diseases and sexual behavior: insights from mathematical models. Journal of Infectious Diseases 1996; 174:Suppl-61.

(100) Beutner KR, Reitano MV, Richwald GA, Wiley DJ. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clinical Infectious Diseases 1998; 27(4):796-806.

(101) Abba MC, Mouron SA, Gomez MA, Dulout FN, Golijow CD. Association of human papillomavirus viral load with HPV16 and high-grade intraepithelial lesion. International Journal of Gynecological Cancer 2003; 13(2):154-158.

(102) Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. Journal of Infectious Diseases 1998; 178(2):551-555.

(103) Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecologic Oncology 2003; 90(2):358-365.

(104) Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstetrics & Gynecology 2002; 100(5:Pt 1):t-71.

(105) Bollen LJ, Tjong AHS, van d, V, Mol BW, ten Kate FW, ter Schegget J et al. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecologic Oncology 1999; 72(2):199-201.

(106) Bodner K, Bodner-Adler B, Wierrani F, Kimberger O, Denk C, Grunberger W. Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis. Anticancer Research 2002; 22(6B):3733-3736.

(107) Jain S, Tseng CJ, Horng SG, Soong YK, Pao CC. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynecologic Oncology 2001; 82(1):177-180. 28

(108) Kjellberg L, Wadell G, Bergman F, Isaksson M, Angstrom T, Dillner J. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. American Journal of Obstetrics & Gynecology 2000; 183(5):1238-1242.

(109) Kucera E, Sliutz G, Czerwenka K, Breitenecker G, Leodolter S, Reinthaller A. Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone? European Journal of Obstetrics, Gynecology, & Reproductive Biology 2001; 100(1):72-76.

(110) Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecologic Oncology 2000; 79(2):294-299.

(111) Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang KG, Huang HJ et al. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. American Journal of Obstetrics & Gynecology 2001; 184(5):940-945.

(112) Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papillomavirus and recurring genital warts. New England Journal of Medicine 1985; 313(13):784-788.

(113) Colgan TJ, Percy ME, Suri M, Shier RM, Andrews DF, Lickrish GM. Human papillomavirus infection of morphologically normal cervical epithelium adjacent to squamous dysplasia and invasive carcinoma. Human Pathology 1989; 20(4):316-319.

(114) Mitchell MF, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H, Silva E. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstetrics & Gynecology 1998; 92(5):737-744.

(115) Wright TC, Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ, ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287(16):2120-2129.

(116) Krebs HB, Helmkamp BF. Treatment failure of genital condylomata acuminata in women: role of the male sexual partner. American Journal of Obstetrics & Gynecology 1991; 165(2):337-339.

(117) National Institute of Allergy and Infectious Diseases. Workshop Summary: Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention.: 2001.

(118) Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sexually Transmitted Diseases 2002; 29(11):725-735.

(119) Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL, Jr. et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. American Journal of Obstetrics & Gynecology 2001; 185(2):380-385.

(120) Radcliffe KW, Ahmad S, Gilleran G, Ross JD. Demographic and behavioural profile of adults infected with chlamydia: a case-control study. Sexually Transmitted Infections 2001; 77(4):265-270.

(121) Wald A, Langenberg D, Kexel E, Izu A, Ashley R, Corey L. [abstract B9E] National STD Prevention Conference, San Diego, CA, March 4-7, 2002. 3-4-0002.

(122) Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285(24):3100-3106.

(123) Warner L, Newman DR, Austin HA, Kamb ML, Douglas JM, Malotte CK et al. Condom Effectiveness for Reducing Transmission of Gonorrhea and Chlamydia: The Importance of Assessing Partner Infection Status. American Journal of Epidemiology. In press.

(124) Williams KM, Wingood GM, DiClemente RJ, Crosby RA, Hubbard MD, Liau A et al. Prevalence and correlates of Chlamydia trachomatis among sexually active African-American adolescent females. Preventive Medicine 2002; 35(6):593-600.

(125) Lytle CD, Duff JE, Fleharty B, Bidinger RL, Cyr WH, Routson LB. A sensitive method for evaluating condoms as virus barriers. Journal of AOAC International 1997; 80(2):319-324.

(126) Lytle CD, Routson LB, Seaborn GB, Dixon LG, Bushar HF, Cyr WH. An in vitro evaluation of condoms as barriers to a small virus. Sexually Transmitted Diseases 1997; 24(3):161-164.

(127) Kennedy L, Buntine DW, O'Connor D, Frazer IH. Human papillomavirus--a study of male sexual partners. Medical Journal of Australia 1988; 149(6):309-311.

(128) Krebs HB, Schneider V. Human papillomavirus-associated lesions of the penis: colposcopy, cytology, and histology. Obstetrics & Gynecology 1987; 70(3:Pt 1):t-304.

(129) Schultz RE, Miller JW, MacDonald GR, Auman JR, Peterson NR, Ward BE et al. Clinical and molecular evaluation of acetowhite genital lesions in men. Journal of Urology 1990; 143(5):920-923.

(130) Zenilman JM, Weisman CS, Rompalo AM, Ellish N, Upchurch DM, Hook EW, III et al. Condom use to prevent incident STDs: the validity of self-reported condom use. Sexually Transmitted Diseases 1995; 22(1):15-21.

(131) Weir SS, Feldblum PJ. Condom use to prevent incident STDs. Sexually Transmitted Diseases 1996; 23(1):76-77.

(132) Galavotti C, Cabral R, Beeker C. Condom use to prevent incident STDs. Sexually Transmitted Diseases 1996; 23(1):77-79.

(133) Turner CF, Miller HG. Zenilman's anomaly reconsidered: fallible reports, ceteris paribus, and other hypotheses. Sexually Transmitted Diseases 1997; 24(9):522-527.

(134) Peterman TA, Lin LS, Newman DR, Kamb ML, Bolan G, Zenilman J et al. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Project RESPECT Study Group. Sexually Transmitted Diseases 2000; 27(8):446-451.

(135) Schneider A, Kirchhoff T, Meinhardt G, Gissmann L. Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears. Obstetrics & Gynecology 1992; 79(5:( Pt 1):t-8.

(136) Adam E, Berkova Z, Daxnerova Z, Icenogle J, Reeves WC, Kaufman RH. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. American Journal of Obstetrics & Gynecology 2000; 182(2):257-264.

(137) Becker TM, Wheeler CM, McGough NS, Parmenter CA, Jordan SW, Stidley CA et al. Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women. JAMA 1994; 271(15):1181-1188.

(138) Donnan SP, Wong FW, Ho SC, Lau EM, Takashi K, Esteve J. Reproductive and sexual risk factors and human papilloma virus infection in cervical cancer among Hong Kong Chinese. International Journal of Epidemiology 1989; 18(1):32-36.

(139) Evans BA, Tasker T, MacRae KD. Risk profiles for genital infection in women. Genitourinary Medicine 1993; 69(4):257-261.

(140) Fasal E, Simmons ME, Kampert JB. Factors associated wih high and low risk of cervical neoplasia. Journal of the National Cancer Institute 1981; 66(4):631-636.

(141) Figueroa JP, Ward E, Luthi TE, Vermund SH, Brathwaite AR, Burk RD. Prevalence of human papillomavirus among STD clinic attenders in Jamaica: association of younger age and increased sexual activity. Sexually Transmitted Diseases 1995; 22(2):114-118.

(142) Fonck K, Kidula N, Kirui P, Ndinya-Achola J, Bwayo J, Claeys P et al. Pattern of sexually transmitted diseases and risk factors among women attending an STD referral clinic in Nairobi, Kenya. Sexually Transmitted Diseases 2000; 27(7):417-423.

(143) Hildesheim A, Brinton LA, Mallin K, Lehman HF, Stolley P, Savitz DA et al. Barrier and spermicidal contraceptive methods and risk of invasive cervical cancer. Epidemiology 1990; 1(4):266-272.

(144) Hillman RJ, Ryait BK, Botcherby M, Taylor-Robinson D. Human papillomavirus DNA in the urogenital tracts of men with gonorrhoea, penile warts or genital dermatoses. Genitourinary Medicine 1993; 69(3):187-192.

(145) Hippelainen MI, Hippelainen M, Saarikoski S, Syrjanen K. Clinical course and prognostic factors of human papillomavirus infections in men. Sexually Transmitted Diseases 1994; 21(5):272-279.

(146) Ho GY, Kadish AS, Burk RD, Basu J, Palan PR, Mikhail M et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. International Journal of Cancer 1998; 78(3):281-285.

(147) Juarez-Figueroa LA, Wheeler CM, Uribe-Salas FJ, Conde-Glez CJ, Zampilpa-Mejia LG, Garcia-Cisneros S et al. Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers from Mexico City. Sexually Transmitted Diseases 2001; 28(3):125-130.

(148) Kataja V, Syrjanen S, Yliskoski M, Hippelinen M, Vayrynen M, Saarikoski S et al. Risk factors associated with cervical human papillomavirus infections: a case-control study. American Journal of Epidemiology 1993; 138(9):735-745.

(149) Kjaer SK, de Villiers EM, Dahl C, Engholm G, Bock JE, Vestergaard BF et al. Case-control study of risk factors for cervical neoplasia in Denmark. I: Role of the "male factor" in women with one lifetime sexual partner. International Journal of Cancer 1991; 48(1):39-44.

(150) Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiology, Biomarkers & Prevention 1997; 6(10):799-805.

(151) Kjaer SK, Svare EI, Worm AM, Walboomers JM, Meijer CJ, van den Brule AJ. Human papillomavirus infection in Danish female sex workers. Decreasing prevalence with age despite continuously high sexual activity. Sexually Transmitted Diseases 2000; 27(8):438-445.

(152) Kotloff KL, Wasserman SS, Russ K, Shapiro S, Daniel R, Brown W et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sexually Transmitted Diseases 1998; 25(5):243-250.

(153) Mayaud P, Gill DK, Weiss HA, Uledi E, Kopwe L, Todd J et al. The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sexually Transmitted Infections 2001; 77(4):248-254.

(154) Munoz N, Bosch FX, de Sanjose S, Vergara A, del Moral A, Munoz MT et al. Risk factors for cervical intraepithelial neoplasia grade III/carcinoma in situ in Spain and Colombia. Cancer Epidemiology, Biomarkers & Prevention 1993; 2(5):423-431.

(155) Parazzini F, Negri E, La Vecchia C, Fedele L. Barrier methods of contraception and the risk of cervical neoplasia. Contraception 1989; 40(5):519-530.

(156) Peters RK, Thomas D, Hagan DG, Mack TM, Henderson BE. Risk factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County. Journal of the National Cancer Institute 1986; 77(5):1063-1077.

(157) Sellors J, Mahoney JB, Kacqorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Can Med Assoc J 2000; 163:503-508.

(158) Shlay JC, McGill WL, Masloboeva HA, Douglas JM, Jr. Pap smear screening in an urban STD clinic. Yield of screening and predictors of abnormalities. Sexually Transmitted Diseases 1998; 25(9):468-475.

(159) Slattery ML, Overall JC, Jr., Abbott TM, French TK, Robison LM, Gardner J. Sexual activity, contraception, genital infections, and cervical cancer: support for a sexually transmitted disease hypothesis. American Journal of Epidemiology 1989; 130(2):248-258.

(160) Svare EI, Kjaer SK, Worm AM, Osterlind A, Moi H, Christensen RB et al. Risk factors for HPV infection in women from sexually transmitted disease clinics: comparison between two areas with different cervical cancer incidence. International Journal of Cancer 1998; 75(1):1-8.

(161) Syrjanen K, Vayrynen M, Castren O, Yliskoski M, Mantyjarvi R, Pyrhonen S et al. Sexual behaviour of women with human papillomavirus (HPV) lesions of the uterine cervix. British Journal of Venereal Diseases 1984; 60(4):243-248.

(162) Thomas DB, Ray RM, Pardthaisong T, Chutivongse S, Koetsawang S, Silpisornkosol S et al. Prostitution, condom use, and invasive squamous cell cervical cancer in Thailand. American Journal of Epidemiology 1996; 143(8):779-786.

(163) Wang PD LR. Risk factors for cervical intraepithelial neoplasia in Taiwan. Gynecologic Oncology 1996; 62:10-18.

(164) Wen LM, Estcourt CS, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sexually Transmitted Infections 1999; 75(5):312-316.

(165) Young TK, McNicol P, Beauvais J. Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian aboriginal and non-aboriginal women.[comment]. Sexually Transmitted Diseases 1997; 24(5):293-298.

(166) Zondervan KT, Carpenter LM, Painter R, Vessey MP. Oral contraceptives and cervical cancer--further findings from the Oxford Family Planning Association contraceptive study. British Journal of Cancer 1996; 73(10):1291-1297.

(167) Bleeker MC, Hogewoning CJ, van den Brule AJ, Voorhorst FJ, Van Andel RE, Risse EK et al. Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. Journal of the American Academy of Dermatology 2002; 47(3):351-357.

(168) Hogewoning CJ, Bleeker MC, Van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int.J.Cancer 107, 811-816. 2003.

(169) Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sexually Transmitted Diseases 2002; 29(11):725-735.

(170) Sokal DC, Hermonat PL. Inactivation of papillomavirus by low concentrations of povidone-iodine. Sexually Transmitted Diseases 1995; 22(1):22-24.

(171) Howett MK, Neely EB, Christensen ND, Wigdahl B, Krebs FC, Malamud D et al. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrobial Agents & Chemotherapy 1999; 43(2):314-321.

(172) Christensen ND, Reed CA, Culp TD, Hermonat PL, Howett MK, Anderson RA et al. Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrobial Agents & Chemotherapy 2001; 45(12):3427-3432.

(173) Coutlee F, Voyer H. Effect of nonionic detergents on amplification of human papillomavirus DNA with consensus primers MY09 and MY11. Journal of Clinical Microbiology 1998; 36(4):1164.

(174) Anwar H, Coetzee N, Blanchard K, Dangor Y, de Kock A, Friedland B et al. A randomized, placebo-controlled double-blind expanded safety trial of carraguard microbicide gel in South Africa: RTI/STI at Baseline and Follow-up. [Abstract] May 12-15, 2002.Antwerp, Belgium.

(175) Celentano DD, Klassen AC, Weisman CS, Rosenshein NB. The role of contraceptive use in cervical cancer: the Maryland Cervical Cancer Case-Control Study. American Journal of Epidemiology 1987; 126(4):592-604.

(176) Fairley CK, Gay NJ, Forbes A, Abramson M, Garland SM. Hand-genital transmission of genital warts? An analysis of prevalence data. Epidemiology & Infection 1995; 115(1):169-176.

(177) Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG: an International Journal of Obstetrics & Gynaecology 2002; 109(1):96-98.

(178) Lowy DR, Frazer IH. Chapter 16: Prophylactic human papillomavirus vaccines. Journal of the National Cancer Institute Monographs 2003;(31):111-116.

(179) Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290(6):781-789.

(180) Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerging Infectious Diseases 2003; 9(1):37-48.

(181) Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine 2002; 347(21):1645-1651.

(182) Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. International Journal of STD & AIDS 2003; 14(5):300-306.

(183) Kiviat NB, Critchlow CW, Holmes KK, Kuypers J, Sayer J, Dunphy C et al. Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men. AIDS 1993; 7(1):43-49.

(184) Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003; 97(6):1528-1540.

(185) Seeff LC, McKenna MT. Cervical cancer mortality among foreign-born women living in the United States, 1985 to 1996. Cancer Detection & Prevention 2003; 27(3):203-208.

(186) Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. Ca: a Cancer Journal for Clinicians 2002; 52(6):342-362.

(187) American College of Obstetricians and Gynecologists. Cervical Cytology Screening. Clinical Management Guidelines for Obstetrician-Gynecologists. ACOG Practice Bulletin, No. 45. August, 2003. 2003.

< Last Segment: Prevention | Next Segment: Front Page >